摘要
目的探讨国家药品集中带量采购(简称带量采购)政策执行前后,仿制与原研降压药的使用情况。方法选择上海市某三级甲等综合医院为样本医院,选取既有原研药又有仿制药的9种(21个规格)降压药作为目标药物,分析国家带量采购政策执行前后,仿制药与原研药用药频度占比、使用金额占比、仿制药替代率及费用节省率。结果国家带量采购政策执行后,目标药物中原研药用药频度占比下降58.77%,使用金额减少66.51%;仿制药用药频度占比上升189.56%,金额仅增加19.87%;仿制药替代率由19.03%升至63.39%。目标药物实际节省费用共799.16万元,费用节省率为110.66%,包含带量采购中选品种的药品共节省777.93万元,占目标药物节省费用的97.34%,其中缬沙坦、奥美沙坦酯、比索洛尔、苯磺酸氨氯地平费用节省率均超过150%。结论国家带量采购政策极大地促进了降压药仿制药替代原研药的进展,并显著降低了药品费用,减轻了患者的药费负担。建议加强仿制药替代原研药及国家带量采购政策的宣传,扩大带量采购范围。
Objective To investigate the use of generic and original-patented antihypertensive drugs before and after the implementation of the national centralized drug procurement(NCDP)policy.Methods A gradeⅢ-A general hospital in Shanghai was selected as the sample hospital,and nine kinds(21 specifications)of antihypertensive drugs with both original-patented and generic drugs were selected as the target drugs.The proportions of defined daily doses(DDDs)and total cost of generic and original-patented drugs,the replacement rate of original-patented drugs by generic drugs and cost saving rate before and after the implementation of the NCDP policy were analyzed.Results After the implementation of NCDP policy,the DDDs proportion of original-patented drugs in the target drugs decreased by 58.77%,and the total cost of which decreased by 66.51%.The DDDs proportion of generic drugs increased by 189.56%,and the total cost of which increased by only 19.87%.The replacement rate of original-patented drugs by generic drugs increased from 19.03%to 63.39%.The actual cost savings of target drugs were CNY 7.9916 million,with a cost saving rate of 110.66%.Among these target drugs,the drugs selected in the NCDP policy saved CNY 7.7793 million,accounting for 97.34%of the cost savings of target drugs,of which the cost savings rate of valsartan,olmesartan medoxomil,bisoprolol,benzenesulfonic acid and amlodipine was higher than 150%.Conclusion The NCDP policy greatly promotes the replacement of original-patented antihypertensive drugs by generic drugs,significantly reduces the drug costs and burden of patients.It is suggested to strengthen the publicity of the replacement of original-patented drugs by generic drugs and the NCDP policy,and expand the scope of volume-based procurement.
作者
屈茹楠
高岸
范国荣
戚晨冬
QU Runan;GAO An;FAN Guorong;QI Chendong(Shanghai General Hospital Affiliated to Shanghai Jiao Tong University,Shanghai,China 200080;Jiading Branch of Shanghai General Hospital·Jiangqiao Hospital of Jiading District,Shanghai,China 201803)
出处
《中国药业》
CAS
2022年第15期10-15,共6页
China Pharmaceuticals
基金
上海市临床重点专科建设项目[02.DY11.03.19.03]
上海市2020年度综合医院中西医结合专项项目[ZHYY-ZXYJHZX-202008]。
关键词
国家药品集中带量采购
降压药
原研药
仿制药
药事管理
NCDP
antihypertensive drug
original-patented drug
generic drug
pharmaceutical administration
